… This study evaluated all-cause mortality in hospitalized patients with a mild form of COVID-19
receiving molnupiravir or nirmatrelvir/ritonavir. Each group was matched in a ratio of 1:1 …

… These reviews suggested that molnupiravir reduces the frequency of … COVID-19. WHO's
living guideline recommends use of molnupiravir in outpatients with mild-to-moderate COVID-19 …

… : Molnupiravir (MK-4482) is an investigational direct-acting antiviral agent that is under
development for the treatment of COVID-19. … shortest possible synthesis to molnupiravir, and was …

… for mild COVID-19 patients treated with molnupiravir compared to those treated with SOC …
examining the efficacy of molnupiravir in Indian patients with mild COVID-19 carried out by …

… assess the efficacy and safety of molnupiravir in patients with mild or moderate COVID-19. …
of molnupiravir in treating patients with mild-to-moderate COVID-19. Our findings reveal that …

… a prescription for molnupiravir within five days … covid-19 antiviral or antibody treatment within
the first 30 days of infection (n=217 814). We evaluated whether treatment with molnupiravir …

… We conducted additional analyses to evaluate additional potential benefits of molnupiravir
for the treatment of mild to moderate COVID-19 based on clinical markers and the need for …

… to know, how to use molnupiravir in people with COVID-19. Following questions and answers
should help making practical guideline on use of molnupiravir in people with COVID-19. …

… efficacy and safety of molnupiravir for the treatment of non-severe (mild or moderate)
COVID-19, and conduct subgroup analyses and meta-regression for COVID-19 patients with high …

… Objectives: Below we report our experience in the use of molnupiravir, the … treatment of
patients with COVID-19. Materials and Methods: We enrolled patients diagnosed with COVID-19 …